News archive
Showing 796 results
January 2026
-
Media Release
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1 Distinction expedites development and review of treatments for serious… -
Media Release
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT…
December 2025
-
Media Release
Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company… -
Media Release
Novartis breaks ground on flagship manufacturing hub in North Carolina
FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to… -
Media Release
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients… -
Media Release
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall… -
Story
Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future
As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.
November 2025
-
Media Release
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world… -
Media Release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studies One-time dose of Itvisma… -
Media Release
Novartis announces plans to build flagship manufacturing hub in North Carolina
Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic… -
Story
Community Health Solutions: How We’re Meeting People Where They Are to Improve Community Health
Learn how community-driven partnerships are helping to break down barriers and support access to health care.
-
Story Education and Awareness
Five questions with Eden Wells, Chief Insights and Decision Science Officer at Novartis US
In this interview, Eden discusses the pivotal moments that shaped her career, her passion for advancing patient care and her vision for a future where timely and accessible healthcare is a reality for everyone.